Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Acer Therapeutics Inc

Current price
0.66 USD -0.14 USD (-17.95%)
Last closed 0.8 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 16 148 488 USD
Yield for 12 month -57.96 %
21.11.2021 - 28.11.2021

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts. As of November 17, 2023, Acer Therapeutics Inc. operates as a subsidiary of Zevra Therapeutics, Inc. Address: One Gateway Center, Newton, MA, United States, 02458


WallStreet Target Price

1.5 USD

P/E ratio

Dividend Yield

3.5 %

Current Year

Last Year

+1 260 000 USD

Current Quarter

+371 790 USD

Last Quarter

Current Year

Last Year

+1 260 000 USD

Current Quarter

+287 985 USD

Last Quarter

Key Figures ACER

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -19 733 236 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -65.27 %
PEG Ratio
Return On Equity TTM -472.99 %
Wall Street Target Price 1.5 USD
Revenue TTM 360 000 USD
Book Value -1.36 USD
Revenue Per Share TTM 0.024 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield 3.5 %
Gross Profit TTM 1 260 000 USD
Earnings Share -1.93 USD
Diluted Eps TTM -1.93 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ACER

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACER

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 3.5 %
Last Split Factor 1:10.35553
Payout Ratio
Last Split Date 21.09.2017
Dividend Date 21.09.2017

Stock Valuation ACER

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 102.7606
Price Sales TTM 174.5231
Enterprise Value EBITDA -1.561
Price Book MRQ 17.2561

Financials ACER

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ACER

For 52 weeks

0.55 USD 4.56 USD
50 Day MA 0.81 USD
Shares Short Prior Month 529 131
200 Day MA 0.97 USD
Short Ratio 2.87
Shares Short 493 549
Short Percent 2.61 %